Literature DB >> 25902041

Arg⁹⁷² insulin receptor substrate-1 inhibits endothelial nitric oxide synthase expression in human endothelial cells by upregulating microRNA-155.

Cheng Huang1, Guang Li1, Haojian Dong1, Shuo Sun1, Haimin Chen1, Demou Luo1, Ling Sun1, Xida Li1, Zhujun Chen1, Huijian Yang1, Shuisheng Wei1, Yingling Zhou1.   

Abstract

The dysregulation of nitric oxide (NO) synthesis attributable to the abnormal expression/activity of endothelial NO synthase (eNOS) is considered to be a major characteristic of insulin-resistant states, as well as an essential contributor to the pathogenesis of cardiovascular diseases. The Arg972 insulin receptor substrate-1 (IRS-1) is associated with insulin resistance. In the present study, we investigated the association between Arg972 IRS-1 and eNOS expression/activity in human subjects and in primary cultures of human endothelial cells. Data from 832 human subjects revealed that heterozygous and homozygous Arg972 IRS-1 carriers had significantly lower levels of plasma eNOS and nitrite/nitrate than the homozygous wild-type (WT) IRS-1 carriers. Human umbilical vein endothelial cells (HUVECs) established from delivering mothers expressing heterozygous Arg972 IRS-1 had significantly lower eNOS expression/activity and higher miR-155 levels than those expressing WT homozygous IRS-1. The overexpression of IRS-1 and Arg972 IRS-1 in the HUVECs, respectively, decreased and increased the miR-155 expression level. In addition, the overexpression of IRS-1 in the HUVECs significantly increased eNOS expression; this effect was reversed by transfection with mature miR-155 mimic or treatment with the selective phosphatidylinositol-3 kinase (PI3K) inhibitor, BKM120. On the other hand, the overexpression of Arg972 IRS-1 markedly decreased eNOS expression and this effect was reversed by transfection with antagomir-155. On the whole, our in vivo data demonstrate that Arg972 IRS-1 is associated with decreased plasma eNOS and nitrite/nitrate levels in human subjects. Our in vitro data demonstrate that Arg972 IRS-1 inhibits eNOS expression in human endothelial cells by upregulating miR-155 expression through the impairment of PI3K signaling. The present study provides new insight into the pathophysiological role of Arg972 IRS-1 in cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25902041     DOI: 10.3892/ijmm.2015.2192

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  The impact of insulin resistance on the kidney and vasculature.

Authors:  Ferruh Artunc; Erwin Schleicher; Cora Weigert; Andreas Fritsche; Norbert Stefan; Hans-Ulrich Häring
Journal:  Nat Rev Nephrol       Date:  2016-10-17       Impact factor: 28.314

2.  miR-155 Deletion in Female Mice Prevents Diet-Induced Obesity.

Authors:  Andrew D Gaudet; Laura K Fonken; Liubov V Gushchina; Taryn G Aubrecht; Santosh K Maurya; Muthu Periasamy; Randy J Nelson; Phillip G Popovich
Journal:  Sci Rep       Date:  2016-03-08       Impact factor: 4.379

Review 3.  Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage.

Authors:  Cecilia Nigro; Alessia Leone; Gregory Alexander Raciti; Michele Longo; Paola Mirra; Pietro Formisano; Francesco Beguinot; Claudia Miele
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

Review 4.  Macrophages, Low-Grade Inflammation, Insulin Resistance and Hyperinsulinemia: A Mutual Ambiguous Relationship in the Development of Metabolic Diseases.

Authors:  Gerhard Paul Püschel; Julia Klauder; Janin Henkel
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

5.  Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Jiaxin Zong; Yingdan Tang; Tong Wang; Inam Ullah; Ke Xu; Jing Wang; Pengsheng Chen; Zengguang Chen; Tiantian Zhu; Jun Chen; Jimin Li; Fei Wang; Lu Yang; Yuansheng Fan; Lu Shi; Xiaoxuan Gong; John W Eikelboom; Yang Zhao; Chunjian Li
Journal:  J Am Heart Assoc       Date:  2022-08-05       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.